3rd international conference on dengue and dhf schedule-15 sep 13-approved.pdf
DESCRIPTION
3RD INTERNATIONAL CONFERENCE ON DENGUETRANSCRIPT
(Tentative) Scientific Program for the 3rd International Conference on Dengue/DHF 21-23 Oct 2013 [update on 15 September 2013]
Time Queen's Park 1 Queen's Park 2 Queen's Park 3 Queen's Park 4-5
08.00-09.00
Welcome Address:
Report by:
Opening remark: Dr. Samlee Plianbangchang (Regional Director of WHO/SEARO)
Opening speech: (Minister of Public Health)
10.30-11.00
12.00-13.00
13.00-13.45
14.30-17.30 Symposium 1: Global Dengue Situation 14.30-16.00 Symposium 2: Highlight from Fifty Years of Dengue
Experience and Research at Queen Sirikit National Institute of
Child Health
14.30-16.00 Symposium 3: Emerging Flavivirus and
Epidemiology of DENV
Special Symposium by DVI: Generating Evidence for Decision
Making regarding the Introduction of Dengue Vaccines
Chair: Duane Gubler (USA)
Co-chair: Kamnuan Ungchusak (THA)
Chair: Timothy Endy (USA)
Co-chair: Siraporn Sawadiworn (THA)
Chair: Pratap Singhasivanont (THA)
Co-chair: Richard G Jarman (USA)
Chair: Georges Thiry (BEL)
Co-chair: Pornthep Chanthavanich (THA)
14.30-15.00 Duane Gubler (USA)
Dengue - Global health problem and threat
14.30-15.00 Suchitra Nimmannitya (THA)
Interweaving clinical experience with research works in dengue:
Towards best achievement
14.30-14.45 (0215R01) Basu Dev Pandey (NPL)
First isolation of dengue virus from Nepal
14.30-14.50 Pornthep Chanthavanich (THA)
Burden of dengue infection in children and adults in Bang Phae
district, Ratchaburi
14.45-15.00 (0025R01) Nikos Vasilakis (USA)
The daemon in the forest-emergence of a new dengue serotype in
SouthEast Asia
14.50-15.10 (0220R01) Jacqueline Lim (KOR)
Burden of dengue infection in children and adults of Santa Cruz
comuna of Medellin, Columbia
15.00-15.20 A P Dash (WHO/SEARO)
Dengue in South East Asia
15.00-15.30 In-Kyu Yoon (USA)
Insights into host and viral factors in dengue severity
15.00-15.15 (0145R01) Robert Reiner (USA)
Estimating time-varying epidemiological parameters of dengue virus
using longitudinal serological data
15.15-15.30 (0116R01) Bernard Cazelles (FRA)
Rural origin of the propagation of dengue in SouthEast Asia
15.10-15.30 (0267R01) Vittal Mogasale (IND)
A multi-country study of the economic burden of dengue fever and
household willingness to pay for dengue vaccines
15.20-15.40 (WHO/WPRO)
Dengue in Western Pacific15.30-16.00 Anon Srikiatkhachorn (THA)
Clinical and immunologic studies in dengue at Queen Sirikit National
Institute of Child Health
15.30-15.45 (0246R01) Sowath Ly (KHM)
Epidemiology of clusters in identified dengue cases' households in
rural Cambodia, 2013 - preliminary results
15.30-15.50 Nyambat Batmunkh (MNG)
Update on the DVI activity in Brazil “Ensuring rapid introduction of
dengue vaccines through first-to-introduce countries”
15.40-16.00 Kay Tomashek (PRI)
Emerging of dengue in USA
-To be continued after coffee break-15.45-16.00 (0257R01) Alex Perkins (USA)
Impacts of dengue infection on human mobility
16.00-16.30
16.30-17.20 Symposium 1: Global Dengue Situation (Continued) 16.30-17.30 Symposium 4: Lessons Learned from Cohort
Studies
16.30-17.30 Symposium 5: Health Economic Communication &
Community Empowerment
16.30-17.30 Symposium 6: Epidemiology
Chair: Anon Srikiatkhachorn (THA)
Co-chair: Timothy Endy (USA)
Chair: Amara Soonthorndhada (THA)
Co-chair: Chiu-Wan Ng (MYS)
Chair: Wichai Satimai (THA)
Co-chair: Sopon Iamsiritaworn (THA)
16.30-16.50 Harold Margolis (USA)
Dengue in Africa
16.30-16.50 Timothy Endy (USA)
Lessons learned from prospective cohort studies on dengue
transmission and disease severity
16.30-16.50 Chiu-Wan Ng (MYS)
Would economic burden of dengue infections in Malaysia do?
16.30-16.50 Karen Campbell (USA)
Using a dengue transmission model to inform prevention policy and
decision making
16.50-17.20 Raman Velayudhan (WHO/GENEVA)
Global strategy for dengue prevention and control
16.50-17.10 In-Kyu Yoon (USA)
What we have learned from dengue cluster studies
16.50-17.10 Veerle Vanlerberghe (BEL)
Household uptake and use of intervention tools influencing the scale
of effect of dengue vector control
16.50-17.10 Rome Buathong (THA)
Seroprevalence and risk factors of dengue infection in Rayong,
Thailand, 2010
17.10-17.30 Chukiat Sirivichayakul (THA)
Clinical manifestration of dengue; A cohort study
17.10-17.25 (0229R01) Packierisamy Raviwharmman (MYS)
Comparing cost of dengue vector control services between different
delivery agencies in Malaysia
17.10-17.30 Hasitha Tissera (LKA)
Epidemiology of dengue in Sri Lanka: Evolution into a major public
health and clinical entity
19.00-21.30
Day 1: 21 October 2013
09.00-10.30
Break
11.00-12.00
Welcome Dinner
Break
Luncheon Symposium 1
Poster Presentation
13.45-14.30
Chair: Prof. Emeritus Prasert Thongcharoen (Chair of Scientific Organizing Committee)
16.30-17.30
14.30-16.00
REGISTRATION
OPENING CEREMONY
SPECIAL LECTURE
Scott B Halstead (USA) The basic science behind successful dengue vaccine
13.45-14.30 Prof. Natth Bhamarapravati Memorial Lecture
13.45-14.10 Jean Lang (FRA) Thailand : Three decades at the forefront of dengue vaccine development
14.10-14.30 Sutee Yoksan (THA) Prof. Natth's initiation and achievement on dengue vaccine development
Page 1 of 5
Time Queen's Park 1 Queen's Park 2 Queen's Park 3 Queen's Park 4-5
Day 1: 21 October 2013
State-of-the-Art Lecture 1: 08.30-09.30 Symposium 7: Laboratory Diagnosis 08.30-09.30 Symposium 8: Activation and Evasion of Innate
Immunity by Dengue Virus
08.30-09.30 Symposium 9: Vaccine I
Chair: Ichiro Kurane (JPN)
Co-chair: Ananda Nisalak (THA)
Chair: Kenneth Rock (USA)
Co-chair: Anon Srikiatkhachorn (THA)
Chair: Sutee Yoksan (THA)
Co-chair: In-Kyu Yoon (USA)
08.30-09.15 Donald Roberts (USA)
The continuing need for public health insecticides in dengue control?
08.30-09.00 Ichiro Kurane (JPN)
An overview on dengue diagnosis
08.30-08.50 Douglas Golenbock (USA)
Innate immunity and infectious diseases
08.30-08.45 (0114R01) Suh-Chin Wu (TWN)
Reduced mouse neurovirulence and enhanced heparin binding for
dengue type 4 viruses containing the adaptive mutations(s) form
MRC-5 cells
08.50-09.10 Chia-Yi Yu (TWN)
Activation and evasion of type I interferon response in dengue virus
infection
08.45-09.00 (0142R01) Tamaki Okabayashi (JPN)
The evolution of dengue virus serotype 2 in Thailand: a possible
explanation of a 75% solution of dengue vaccine development
09.00-09.30 Stefan Fernandez (USA)
Experience on diagnostic assays and value of rapid test for dengue
diagnosis
09.10-09.30 Panisadee Avirutnan (THA)
Complement response in dengue - a double edged sword
09.00-09.15 (0252R01) Martha Erika Navarro Sanchez (USA)
Optimization of dengue E protein-based immunogens
09.15- 10.30 Symposium 10: Innovative Vector Control and
Approaches
09.30-10.30 Symposium 11: Laboratory Diagnosis 09.30-10.30 Symposium 12: The Roles of Adaptive Immunity in
Protection and Disease
09.30-10.30 Symposium 13: Vaccine II
Chair: Tom Scott (USA)
Co-chair: Suvit Limawongpranee (THA)
Chair: Umesh Chaturvedi (IND)
Co-chair: Uraiwan Kositanont (THA)
Chair: Prida Malasit (THA)
Co-chair: Panisadee Avirutnan (THA)
Chair: Nopporn Sittisombut (THA)
Co-chair: Chukiat Sirivichayakul (THA)
09.15-09.40 Nicole Achee (USA)
Spatial repellent products for dengue control
09.30-09.45 (0310R01) Elizabeth Hunsperger (PRI)
Evaluation of commercially available dengue diagnostic tests for
detection of NS1 antigen and anti-DENV IgM: a WHO/TDR multi-
center study
09.30-09.50 Juthatip Mongkolsapaya (THA)
The human antibody response to dengue virus
09.30-09.45 (0186R01) Navin Khanna (IND)
Dengue virus envelope-based VLP vaccine
09.40-10.10 Vincent Corbel (FRA)
Molecular basis of insecticide resistance in Aedes aegypti and impact
on space spray efficacy09.45-10.00 (0154R01) Anne-Claire Andries (KHM)
Use of urine and saliva for the diagnosis of dengue infection09.50-10.10 Alan Rothman (USA)
Prospective studies of human T cell responses to dengue-what are
the implications for vaccines and therapeutics?
09.45-10.00 (0347R01) Chonlatip Pipattanaboon (THA)
Epitope mapping of human monoclonal antibodies generated from
dengue patients for ideal vaccine development
10.10-10.30 Micheal J Bangs (USA)
Past, current and innovative approaches to a persistent challenge-
dengue vector control
10.00-10.15 (0155R01) Kebaneilwe Lebani (AUS)
Development of a serotyping NS1 captuer assay for diagnosis of
acute, primary dengue virus infections
10.10-10.30 Izabela Rodenhuis-Zybert (NLD)
New insights in antibody-dependent enhancement of dengue virus
infection
10.00-10.15 (0363R01) Robert Beatty (USA)
Dengue virus NS1 as a vaccine to prevent NS1-induced toxicity
10.15-10.30 (0218R01) Ada Alves (BRA)
Mapping the protective immune response induced by a DNA vaccine
against dengue 2 based on the NS1 protein
10.30-11.00
11.00-12.00 Symposium 14: Vector Biology and Behavior State-of-the-Art Lecture 2: 11.00-12.00 Symposium 15: Adaptive and Innate Immunity in
Dengue
11.00-12.00 Symposium 16: Dengue Case Management: Points
of Clinicians' Concern
Chair: John P Grieco (USA)
Co-chair: Theeraphap Chareonviriyaphap (THA)
Chair: Kenneth Rock (USA)
Co-chair: Stefan Fernandez (USA)
Chair: Suchitra Nimmannitya (THA)
Co-chair: Sri Rezeki H. Hadinegoro (IDN)
11.00-11.20 Tom Scott (USA)
The interplay between Aedes aegypti ecology and dengue
epidemiology
11.00-11.30 Richard J Kuhn (USA)
Dengue virus structure and dynamics
11.00-11.15 (0130R01) Raphael Zellweger (USA)
Cellular immunity mediates short-term protection against heterologous
dengue re-infection
11.00-11.20 Siripen Kalayanarooj (THA)
Dengue classifications and guidelines of clinical management: original
WHO vs. TDR 2009
11.20-11.40 John P Grieco (USA)
Aedes aegypti behavior : Potential impact on control interventions
11.15-11.30 (0157R01) Daniela Weiskopf (USA)
Comprehensive analysis of dengue-virus specific responses supports
an HLA-linked protective role for CD8+ T cells
11.20-11.40 LakKumar Fernando (LKA)
Guidelines and Beyond: How to deal with some difficult situations
11.40-12.00 Sylvie Manguin (FRA)
Global invasion and biology of the Aedes mosquito and associated
risk of dengue expansion
11.30-12.00 Ralf Bartenschlager (DEU)
New insights into the dengue virus replication cycle
11.30-11.45 (0069R01) Wilawan Chan-in (THA)
Anergy of human invariant natural killer T cells from acute dengue
virus infected patients
11.40-12.00 Tahira Cheema (PAK)
Facing 2011 Lahore dengue epidemic
11.45-12.00 (0275R01) Ruklanthi de Alwis (USA)
Characterization of DENV1 type-specific immunity using a strongly
neutralizing human monoclonal antibody
12.00-13.00
13.00-13.30
Luncheon Symposium 2
Poster Presentation
09.15-10.30
11.00-12.00
Day 2: 22 October 2013
08.30-09.10
Break
Page 2 of 5
Time Queen's Park 1 Queen's Park 2 Queen's Park 3 Queen's Park 4-5
Day 1: 21 October 2013State-of-the-Art Lecture 3: 13.30-15.30 Symposium 17: Biology of Dengue Virus and
Dengue Virus-Host Interaction
13.30-15.35 Symposium 18: Integrated Vector Management (IVM)
Chair: Richard J Kuhn (USA)
Co-chair: Ralf Bartenschlager (DEU)
Chair: Raman Velayudhan (WHO/GENEVA)
Co-chair: A P Dash (WHO/SEARO)
13.30-14.00 Gavin Screaton (GBR)
Overview on pathogenesis of dengue virus infection
13.30-14.00 Rushika Perera (USA)
Alterations in cellular metabolism are keys to dengue virus replication
13.30-13.55 Raman Velayudhan (WHO/GENEVA) Global strategy
on integrated vector management
14.00-15.30 Symposium 19: Vascular Biology of Viral
Hemorrhagic Fevers
14.00-15.30 Symposium 17: (continued) 13.55-15.30 Symposium 18: (continued) 14.00-15.30 Symposium 20: Hematologic Changes in Dengue
Illness
Chair: Gavin Screaton (GBR)
Co-chair: Umesh Chaturvedi (IND)
13.55-14.20 A P Dash (WHO/SEARO)
IVM strategy for dengue prevention and control in WHO South East
Asian countries
Chair: Tanomsri Srichaikul (THA)
Co-chair: LakKumar Fernando (LKA)
14.00-14.25 Hans Schnittler (DEU)
Dynamics of endothelial junctions
14.00-14.15 (0028R01) Supranee Phanthanawiboon (JPN)
The NS3/NS4B region of dengue virus type 4 laboratory strain is a
determinant for efficient replication
14.00-14.30 Suchitra Nimmannitya (THA)
DHF-a unique viral hemorrhagic fever with pathophysiologic hallmarks
of plasma leakage and hematologic derangement
14.25-14.50 Christina Spiropoulou (USA)
Disruption of the endothelial cell barrier by Hantavirus infection
14.15-14.30 (0219R01) Kenneth Hodge (THA)
Exploration of the dengue RDRP-RNA interface essential for viral
replication
14.20-14.45 Raman Velayudhan (WHO/GENEVA)
WHOPES support judiceous use of insecticides according to IVM
strategy
14.30-14.45 (0242R01) Andrea Da Poian (BRA)
Alterations in hepatic lipid metabolism during dengue virus infection
14.30-15.00 Ampaiwan Chuansumrit (THA)
Hematologic derangement in DHF and management on massive
bleeding
14.50-15.15 Anon Srikiatkhachorn (THA)
Interactions between virus, immunity, and endothelium in dengue
14.45-15.00 (0140R01) Andrew Davidson (GBR)
High throughput quantitative proteomic analysis of dengue virus- host
cell interactions
14.45-15.10 Christina Liew (SGP)
Integrated vector management for dengue control in Singapore
15.00-15.15 (0284R01) Pornapat Surasombatpattana (FRA)
Role of saliva in dengue transmission 15.10-15.35 Boonserm Aumaung (THA) : Implementation of IVM
strategy for dengue prevention and control in Thailand
15.00-15.30 Tanomsri Srichaikul (THA)
Bone marrow involvement and hemophagocytic syndrome in dengue
15.30-16.00
16.00-17.35 Symposium 21: Pathogenesis 16.00-17.30 Symposium 22: Vector and Vector Control 16.00-17.30 Symposium 23: Next Generation Dengue Vaccines 16.00-19.00 Round Table Discussion on The Two
Classifications: DF/DHF/DSS VS. Mild/Severe Dengue
Chair: Guey-Chuen Perng (TWN)
Co-chair: Umesh Chaturvedi (IND)
Chair: Micheal Bangs (USA)
Co-chair: Chitapa Ketavan (THA)
Chair: Lance Gordon (USA)
Co-chair: Kristen M Bauer (USA)
Chair: Scott B Halstead (USA)
Co-chair: Pratap Singhasivanont (THA)
16.00-16.20 Guey-Chuen Perng (TWN)
Bone marrow stem/ progenitor cells in dengue pathogenesis
16.00-16.15 (0123R01) Ahbi Rami Rattanam (MYS)
Evaluation of biological activity of Ipomoea Cairica (Linn.) extract
against dengue vectors
16.00-16.30 In-Kyu Yoon (USA)
Walter Reed Army Institute of Research Dengue Vaccine
Development Efforts
Suchitra Nimmannitya (THA) and Hasitha Tissera (LKA)
16.20-16.50 Prida Malasit (THA) and Khin Saw Aye (MMR)
Immuno-Histopathology studies of 13 autopsy cases of patients died
of dengue hemorrhagic fever
16.15-16.30 (0137R01) Emmanuel Elanga Ndille (BEN)
Human antibody response to Aedes aegypti salivary peptide as a
new indicator for assessing the risk of arboviruses transmission and
the efficacy of vector control, in dengue and chikungunya
transmission areas
Siripen Kalayanarooj (THA) and LakKumar Fernando (LKA)
Anon Srikiatkhachorn (THA)
16.30-16.45 (0045R01) Natapong Jupatanakul (USA)
Laboratory adaptation leads to global transcriptomic down -regulation
and dengue vector capacity changes in Aedes aegypti
16.30-17.00 Nopporn Sittisombut (THA)
Generation and immunogenicity testings of insect cell-derived dengue
virus-like particles
Tran Tinh Hien (VNM)
16.50-17.05 (0240R01) Eugenia Ong (SGP)
SYK-ING pathways for antibody-enhanced dengue virus infection
16.45-17.00 (0112R01) George Dimopoulos (USA)
The Aedes aegypti microbiome and its potential for dengue control
17.05-17.20 (0391R01) Ashutson Biswas (IND)
Pathogenesis of severity in DF/DHF/DSS: A case control study
17.00-17.15 (0112R02) George Dimopoulos (USA)
Targeting conserved human and mosquito host factors with drugs for
dengue control
17.00-17.30 Janine R Danko (USA)
A Phase I clinical trial of tetravalent dengue DNA vaccine with
Vaxfectin
17.20-17.35 (0129R01) Henry Stephens (GBR)
HLA CLASS I supertype profiles in Thai dengue patients
17.15-17.30 (0110R01) Christine Joyce Hernandez (PHL)
Community dengue "HOTSPOT" in The Philippines: a strategic area
for vector control
13.00-14.00
14.00-15.30
16.00-19.00
Break
Page 3 of 5
Time Queen's Park 1 Queen's Park 2 Queen's Park 3 Queen's Park 4-5
Day 1: 21 October 2013
State-of-the-Art lecture 4: 8.30-9.30 Symposium 24: Clinical and Laboratory Diagnosis
Chair: Usa Thisyakorn (THA)
Co-chair: Sri Rezeki H. Hadinegoro (IDN)
08.30-09.00 John Aaskov (AUS)
How does dengue evolution tell us about a successful dengue
vaccine strategy?
08.30-08.45 (0211R01) Kalamathy Murugananthan (LKA)
Virological and immunological profiles in dengue fever suspected
patients from the northern province of Sri Lanka
09.00-10.30 Symposium 25: Vector and Vector Control
08.45-09.00 (0073R01) Pugpen Sirikutt (THA)
Serum lactate and lactate dehydrogenase (LDH), Parameters for
prediction of dengue severity
Chair: Nicole Achee (USA)
Co-chair: Alongkot Ponlawat (THA)
09.00-09.30 Joachim Hombach (WHO/GENEVA)
Global perspective on dengue vaccine development and introduction
09.00-09.15 (0371R01) Peter Ryan (AUS)
Using Wolbachia infections to control dengue transmission
09.00-09.15 (0189R01) Elizabeth Hunsperger (PRI)
Evaluation of the performance available dengue diagnostic tests for
the development of an optimal diagnostic algorithm from a single
specimen
09.15-09.30 (0193R01) Elizabeth Hunsperger (PRI)
Comparison of dengue virus vector competence of Aedes
mediovittatus, the Caribbean treehole mosquito, and Aedes aegypti
09.15-09.30 (0147R01) Kay Tomashek (PRI)
Dengue virus incubation periods: variability by temperature and
serotype
09.30-10.30 Symposium 26: Dengue Vaccine Under Clinical
Trials I
09.30-10.30 Symposium 27: Tools for Vaccine Trial 09.30-10.30 Symposium 25: (Continued) 09.30-10.30 Symposium 28: Dengue Virus Evolution and
Epidemiology
Chair: Joachim Homach (WHO/GENEVA)
Co-chair: Arunee Sabchareon (THA)
Chair: Umesh Chaturvedi (IND)
Co-chair: Nopporn Sittisombut (THA)
Chair: Duncan R Smith (GBR)
Co-chair: Richard G Jarman (USA)
09.30-09.50 Charung Muangchana (THA)
Use of the first dengue vaccine in Thailand
09.30-09.50 Sujan Shresta (USA)
The Role of cellular and humoral immunity in dengue vaccination
09.30-09.45 (0226R01) Gerhart Knerer (GBR)
Impact of combined vector-control and vaccination straqtegies on
transmission dynamics of dengue fever in Thailand - a modelling study
09.30-09.50 Richard G Jarman (USA)
Evolution of dengue viruses in defined geographical space in Thailand
09.50-10.10 Melanie Saville (FRA)
Update on Sanofi Pasteur dengue vaccine development
09.50-10.05 (0096R01) Takeshi Kurosu (JPN)
Animal model for dengue virus infection and evaluation of therapeutics
09.45-10.00 (0271R01) Dawn M Wesson (USA)
Validation of an attractive lethal ovitrap (ALOT) for dengue control in
Iquitos, Peru09.50-10.05 (0039R01) Malayvanh Lao (LAO)
Detection and typing of dengue strains in Vientiane capital, LAO PDR
10.10-10.30 Arunee Sabchareon (THA)
Understanding the first dengue vaccine efficacy trial
10.05-10.20 (0248R01) Kuan Rong Chan (SGP)
The involvement of FCGAMMARIIB in dengue virus neutralization
10.00-10.15 (0181R01) Wasana Boonyuan (THA)
Excito - repellency of thai essential oils against Aedes aegypti (L.)
field population in Thailand
10.05-10.20 (0255R01) Eng Eong Ooi (SGP)
Viral determinants of epidemic dengue
10.15-10.30 (0183R01) Sunaiyana Sathantriphop (THA)
Charaterization of four plant essential oils against Aedes aegypti
10.30-11.00
11.00-12.00 Symposium 29: Dengue Vaccine Under Clinical
Trials II
11.00-12.00 Symposium 30: Clinical aspects and treatments 11.00-12.00 Symposium 31: Anti-Dengue Virus Agents 11.00-12.00 Symposium 32: DENV Evolution and Vaccine
Chair: Harold Margolis (USA)
Co-chair: Chukiat Sirivichayakul (THA)
Chair: Siripen Kalayanarooj (THA)
Co-chair: Tahira Cheema (PAK)
Chair: Sukathida Ubol (THA)
Co-chair: Wei-Kung Wang (USA)
Chair: John Aaskov (AUS)
Co-chair: Timothy Endy (USA)
11.00-11.20 Stephen S Whitehead (USA)
NIAID LID/Butantan: Dengue vaccine ph 1, 2
11.00-11.15 (0148R01) Esther Ellis (PRI)
Dengue - associated hemophagocytic lymphohistiocytosis in Puerto
Rico
11.00-11.20 Wei-Kung Wang (USA)
Stem region of dengue virus envelope protein as potential target of
antiviral strategy
11.00-11.15 (0210R01) Thanh Le Viet (VNM)
The emergence of dengue in Hanoi, Vietnam: preliminary results of
serotype surveillance in 2011, 2012
11.20-11.40 Gilad Gordon (USA)
Inviragen DENVax ph 2 "Safety and immunogenicity of DENVax in
diverse age groups and populations"
11.15-11.30 (0325R01) Victor Gan (SGP)
Utility of warning signs in predicting severe dengue and guiding
admission
11.20-11.35 (0009R02) Kazuyoshi Ikuta (JPN)
Human monoclonal antiboies derived from dengue patients mostly
recognize dengue virus envelope domain II with different effects for
the reactivities with this epitope region with substitutions at different
amino acid residues
11.15-11.30 (0264R01) October Sessions (SGP)
Selective pressure from two hosts enforces genetic stability of
dengue virus
11.40-12.00 Jorge Osorio (USA)
Dissecting the immune response to a chimeric dengue vaccine
11.30-11.45 (0266R01) Ananda Wijewickrama (LKA)
Hepatic involvement in adult dengue patients11.35-11.50 (0341R01) Andrew Sayce (GBR)
N-Methoxynonyl-Deoxynojirimycin modulates the innate immune
response to dengue virus: clinical implications
11.30-11.45 (0164R01) Shuzhen Sim (SGP)
Tracking dengue virus intrahost genetic diversity during human-to-
mosquito transmission
11.45-12.00 (0068R01) Steven Moulton (USA)
Noninvasive method for fluid resuscitation monitoring in dengue
hemorrhagic fever: a preliminary report
11.50-12.05 (0224R01) Nuno Santos (PRT)
Dengue virus capsid protein binding to lipid droplets and its inhibition.
Towards a new drug target
11.45-12.00 (0354R01) Luis Mier-y-Teran-Romero (USA)
Vaccine facilitated re-introduction of displaced dengue serotypes
12.00-13.00
13.00-14.00
09.30-10.30
Break
08.30-09.30
11.00-12.05
Luncheon Symposium 3
Poster Presentation
Day 3: 23 October 2013
Page 4 of 5
Time Queen's Park 1 Queen's Park 2 Queen's Park 3 Queen's Park 4-5
Day 1: 21 October 201314.00-14.40 FUNDING and RESEARCH OPPORTUNITIES in DENGUE
14.00-14.20 Cristina Cassetti (NIH) : NIAID Dengue Research Program and Funding Opportunities
14.20-14.40 Georges Thiry (DVI) : DVI's perspective on dengue
15.45-16.00 CLOSING SPEECH: Professor Emeritus Prasert Thongcharoen
14.00-15.45
14.40-15.45 PANEL DISCUSSION
1. Duane Gubler (USA)
2. Raman Velayudhan (WHO/GENEVA)
3. Pratap Singhasivanont (THA)
4. Prida Malasit (THA)
Dr. Supamit Chunsuttiwat (Modulator)
Page 5 of 5